missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD69 Monoclonal Antibody (FN50), PerCP
Mouse Monoclonal Antibody
Brand: Invitrogen™ MA110277
This item is not returnable.
View return policy
Description
This antibody recognizes an extracellular epitope of CD69, an lymphocyte early activation marker.
CD69 (AIM, Active Inducer Molecule) is a gp28/34 disulfide bonded homodimer with a molecular weight of 60 kDa under non-reducing conditions. CD69 contains one or two N linked oligosacaride and the molecule is present on activated platelets. In normal peripheral blood a variable percentage of cells express the CD69 antigen, and it is involved in lymphocyte signal transduction. Expression CD69 is induced upon activation of T lymphocytes, and may play a role in proliferation. Furthermore, the protein may act to transmit signals in natural killer cells and platelets. Alternative splicing results in multiple transcript variants of CD69. Diseases associated with CD69 dysfunction include coccidiodomycosis and asthma.
Specifications
CD69 | |
Monoclonal | |
PerCP | |
CD69 | |
5830438K24Rik; Activation inducer molecule; activation inducer molecule (AIM/CD69); AI452015; AIM; BL-AC/P26; CD69; CD69 antigen; CD69 antigen (p60, early T-cell activation antigen); CD69 molecule; CLEC2C; C-type lectin domain family 2 member C; C-type lectin domain family 2, member C; EA1; early activation antigen CD69; early lymphocyte activation antigen; early T-cell activation antigen p60; GP32/28; leukocyte surface antigen Leu-23; MLR-3; VEA; Very Early Activation Antigen | |
Mouse | |
Size-exclusion chromatography | |
RUO | |
969 | |
4°C, store in dark, DO NOT FREEZE! | |
Liquid |
Flow Cytometry | |
FN50 | |
PBS with 0.2% BSA and 15mM sodium azide | |
Q07108 | |
CD69 | |
anti-μ-stimulated human B lymphocytes. | |
100 Tests | |
Primary | |
Human | |
Antibody | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction